[Form 4] Bio Green Med Solution, Inc. Insider Trading Activity

Rhea-AI Filing Summary

Bio Green Med Solution (BGMS): A 10% owner, Ong Yee Lung, exchanged outstanding warrants for common stock. On November 5, 2025, the holder acquired 467,535 shares of common stock at $0 in a warrant exchange agreement, reported as a direct holding.

The exchange covered 218,000 Series A warrants (exercise price $7.65), 218,000 Series B warrants ($9), and 31,535 Series C warrants ($10.20), each originally exercisable from June 20, 2025 to June 20, 2030. Following the transaction, the reporting person held 467,535 common shares and 0 derivative securities.

Insights

Equity capital markets analyst

Insider converted warrants into 467,535 shares; no derivatives remain.

The filing shows a warrant-for-share exchange on November 5, 2025, resulting in the acquisition of 467,535 common shares at $0. The exchange replaced three warrant series—A ($7.65), B ($9), and C ($10.20)—with common stock, shifting this holder’s exposure from derivatives to equity.

Post-transaction, the holder reports 0 derivative securities and 467,535 directly held shares. The effect on market dynamics depends on future trading decisions; the filing does not specify any sale activity. This is a routine ownership change disclosure rather than a capital raise.

SEC Form 4

FORM 4

UNITED STATES SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549

STATEMENT OF CHANGES IN BENEFICIAL OWNERSHIP

Filed pursuant to Section 16(a) of the Securities Exchange Act of 1934
or Section 30(h) of the Investment Company Act of 1940

OMB APPROVAL

OMB Number:			3235-0287
Estimated average burden
hours per response:			0.5

X

Check this box if no longer subject to Section 16. Form 4 or Form 5 obligations may continue. See Instruction 1(b).

Check this box to indicate that a transaction was made pursuant to a contract, instruction or written plan for the purchase or sale of equity securities of the issuer that is intended to satisfy the affirmative defense conditions of Rule 10b5-1(c). See Instruction 10.

1. Name and Address of Reporting Person^*

Ong Yee Lung

(Last) (First) (Middle)

9 JALAN LAWA 3 TAMAN PELANGI

INDAH ULU TIRAM

(Street)

JOHOR BAHRU N8 81100

(City) (State) (Zip)

2. Issuer Name and Ticker or Trading Symbol
Bio Green Med Solution, Inc. [ BGMS ]

5. Relationship of Reporting Person(s) to Issuer
(Check all applicable)

	Director	X	10% Owner
	Officer (give title below)		Other (specify below)

3. Date of Earliest Transaction (Month/Day/Year)
11/05/2025

4. If Amendment, Date of Original Filed (Month/Day/Year)

6. Individual or Joint/Group Filing (Check Applicable Line)

X	Form filed by One Reporting Person
	Form filed by More than One Reporting Person

Table I - Non-Derivative Securities Acquired, Disposed of, or Beneficially Owned
1. Title of Security (Instr. 3)	2. Transaction Date (Month/Day/Year)	2A. Deemed Execution Date, if any (Month/Day/Year)	3. Transaction Code (Instr. 8)		4. Securities Acquired (A) or Disposed Of (D) (Instr. 3, 4 and 5)			5. Amount of Securities Beneficially Owned Following Reported Transaction(s) (Instr. 3 and 4)	6. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	7. Nature of Indirect Beneficial Ownership (Instr. 4)
			Code	V	Amount	(A) or (D)	Price
Common Stock	11/05/2025		J(1)		467,535	A	$0	467,535	D

Table II - Derivative Securities Acquired, Disposed of, or Beneficially Owned (e.g., puts, calls, warrants, options, convertible securities)
1. Title of Derivative Security (Instr. 3)	2. Conversion or Exercise Price of Derivative Security	3. Transaction Date (Month/Day/Year)	3A. Deemed Execution Date, if any (Month/Day/Year)	4. Transaction Code (Instr. 8)		5. Number of Derivative Securities Acquired (A) or Disposed of (D) (Instr. 3, 4 and 5)		6. Date Exercisable and Expiration Date (Month/Day/Year)		7. Title and Amount of Securities Underlying Derivative Security (Instr. 3 and 4)		8. Price of Derivative Security (Instr. 5)	9. Number of derivative Securities Beneficially Owned Following Reported Transaction(s) (Instr. 4)	10. Ownership Form: Direct (D) or Indirect (I) (Instr. 4)	11. Nature of Indirect Beneficial Ownership (Instr. 4)
				Code	V	(A)	(D)	Date Exercisable	Expiration Date	Title	Amount or Number of Shares
Series A Common Stock Warrants	$7.65	11/05/2025		J(1)			218,000	06/20/2025	06/20/2030	Common Stock	218,000	$0	0	D
Series B Common Stock Warrants	$9	11/05/2025		J(1)			218,000	06/20/2025	06/20/2030	Common Stock	218,000	$0	0	D
Series C Common Stock Warrants	$10.2	11/05/2025		J(1)			31,535	06/20/2025	06/20/2030	Common Stock	31,535	$0	0	D

Explanation of Responses:

1. Reporting Person exchanged 218,000 Series A Common Stock Purchase Warrants, 218,000 Series B Common Stock Purchase Warrants and 31,535 Series C Common Stock Purchase Warrants for 467,535 shares of Common Stock pursuant to a warrant exchange agreement dated November 5, 2025

	/s/ Ong Yee Lung	11/05/2025
	** Signature of Reporting Person	Date
Reminder: Report on a separate line for each class of securities beneficially owned directly or indirectly.
* If the form is filed by more than one reporting person, see Instruction 4 (b)(v).
** Intentional misstatements or omissions of facts constitute Federal Criminal Violations See 18 U.S.C. 1001 and 15 U.S.C. 78ff(a).
Note: File three copies of this Form, one of which must be manually signed. If space is insufficient, see Instruction 6 for procedure.
Persons who respond to the collection of information contained in this form are not required to respond unless the form displays a currently valid OMB Number.

FAQ

What did BGMS (BGMS) disclose in this Form 4?

A 10% owner, Ong Yee Lung, exchanged warrants for 467,535 common shares at $0 on November 5, 2025.

How many BGMS shares were acquired and at what price?

The reporting person acquired 467,535 common shares at $0 per share via a warrant exchange.

Which BGMS warrants were exchanged and what were their terms?

Exchanged: 218,000 Series A ($7.65), 218,000 Series B ($9), 31,535 Series C ($10.20), originally exercisable 06/20/2025–06/20/2030.

What are the reporting person’s BGMS holdings after the transaction?

Post-transaction holdings are 467,535 common shares directly held and 0 derivative securities.

What is the reporting person’s relationship to BGMS?

The filer is a 10% owner.

What transaction code is shown and what does it mean here?

Code J indicates “other” acquisition under a warrant exchange agreement dated November 5, 2025.